Search all trials

Find therapies in clinical trials near you – page 8

Search by disease and location to discover available clinical trials matching your criteria. Updated every day from authoritative EU registries.

recruiting: 3 962
countries: 28
conditions: 2 101

3 962 trials recruiting28 European countries2 101 conditions coveredUpdated today

Quick filters

Hormone receptor positive breast cancer

Not recruiting

InvestigationalNo placebo

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

InvestigationalNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Palbociclib

Contact Research Centre

HER2 positive breast cancer

Not recruiting

Registered drugNo placebo

Study of Atezolizumab, Trastuzumab, and Vinorelbine for Patients with Advanced HER2-Positive Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years
Substances:Atezolizumab

Contact Research Centre

Plasma cell myeloma

Not recruiting

Registered drugNo placebo

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Bortezomib

Contact Research Centre

Triple negative breast cancer+1

Not recruiting

Investigational

Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Niraparib Tosilate Monohydrate

Contact Research Centre

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Not recruiting

Investigational

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Sodium Iodide

Contact Research Centre

Chronic obstructive pulmonary disease

Not recruiting

Investigational

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Investigational

Spain

Participants:18–64 years · 65+ years
Substances:Itepekimab

Contact Research Centre

Breast cancer+7

Not recruiting

Registered drugNo placebo

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capecitabine

Contact Research Centre

Hormone receptor positive HER2 negative breast cancer

Not recruiting

Registered drugNo placebo

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Palbociclib

Contact Research Centre

Non-small cell lung cancer+2

Not recruiting

Registered drugNo placebo

Study on the Safety of Continued Treatment with GME751 (Pembrolizumab Biosimilar) for Patients with Melanoma or Non-Small Cell Lung Cancer

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Pembrolizumab

Contact Research Centre

Breast cancer

Not recruiting

Registered drugNo placebo

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Durvalumab

Contact Research Centre

Breast cancer

Not recruiting

Registered drugNo placebo

Study on Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Standard Treatment Progression

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Capivasertib

Contact Research Centre

Hormone receptor positive breast cancer+1

Not recruiting

Registered drugNo placebo

Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

Registered drugNo placebo

Spain

Participants:18–64 years · 65+ years
Substances:Neratinib

Contact Research Centre

Find therapies in clinical trials near you – page 8

150 trials match your criteria

Hormone receptor positive breast cancer

Study on Palbociclib and Endocrine Therapy for Patients with HR+/HER2- Early Breast Cancer

HER2 positive breast cancer

Study of Atezolizumab, Trastuzumab, and Vinorelbine for Patients with Advanced HER2-Positive Breast Cancer

Plasma cell myeloma

Study comparing iberdomide, daratumumab and dexamethasone versus daratumumab, bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma

Triple negative breast cancer+1

Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Study on the Effects of FDY-5301 for Patients with Anterior ST-Elevation Myocardial Infarction (Heart Attack)

Chronic obstructive pulmonary disease

Study on Itepekimab for Former Smokers with Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Breast cancer+7

Study of Sacituzumab Govitecan compared to standard therapy in HER2-negative breast cancer patients with high risk of relapse after neoadjuvant treatment

Hormone receptor positive HER2 negative breast cancer

Study Comparing Ribociclib and Palbociclib for Patients with Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer

Non-small cell lung cancer+2

Study on the Safety of Continued Treatment with GME751 (Pembrolizumab Biosimilar) for Patients with Melanoma or Non-Small Cell Lung Cancer

Breast cancer

Study on the Effectiveness and Safety of Olaparib Alone and with Durvalumab for Patients with Early Stage HER2-Negative Breast Cancer with BRCA Mutations

Breast cancer

Study on Capivasertib and Fulvestrant for Patients with Advanced HR+/HER2- Breast Cancer After Standard Treatment Progression

Hormone receptor positive breast cancer+1

Study on Diarrhea Discontinuations in Early-stage HER2+ Breast Cancer Patients Treated with Neratinib, Loperamide, and Colesevelam

Explore other searches

Vaccine trials

Paediatric trials · ages 0–17

Healthy volunteers

Helpful resources

How applying through us works

What happens after you apply

Guides for patients and volunteers

Search filters

Prefer not to search? Our Concierge searches the trials for you.